Category

UF Innovate | Accelerate

Solid Biosciences Joins the Russell 3000® Index

Solid Biosciences Inc., a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases that acquired UF startup AavantiBio, announced it has been added to the broad-market Russell 3000® Index as part of the annual reconstitution, effective July 1st, 2024.

Tech Tuesday: Fire Neural Network

In this week’s Tech Tuesday, UF Innovate host Bethany Gaffey speaks with the CEO of Fire Neural Network about how artificial intelligence is helping to prevent the spread of wildfire.

Gainesville Tech Company Builds International Recognition

Slice Engineering, named the 2023 Tech Company of the Year by the Greater Gainesville Chamber of Commerce, serves tens of thousands of people across the world. Slice is a go-to source for 3D printer parts for NASA, Honda, the U.S. military and many other household names. 

Cordelia Biosciences Wins 2024 Big Idea Competition

UF Innovate | Accelerate client Cordelia Biosciences won first place in this year’s Big Idea Competition. Founded by ecological scientists Jessica Tittl Nielsen (PhD ’24) and Monica Schul (PhD ’25), Cordelia Biosciences is a biotechnical startup that uses natural, microscopic organisms from the ocean to create a sustainable chemical portfolio. The company seeks to safeguard the planet’s ecosystems while revolutionizing the chemical industry.

Florida Venture Forum Announces Record Number of Companies Selected to Present at 2024 Florida Early Stage Venture Conference

Florida Venture Forum, Florida’s largest statewide support organization for investors and entrepreneurs, has announced the companies selected to present at its 2024 Florida Early Stage Venture Conference, being held at the Dr. Phillips Center in Orlando, June 4 – 5.  Two UF Innovate | Accelerate clients -- Silicon Assurance (early stage) and Cordelia Biosciences (collegiate) -- will present.

The Tale of Two Companies: One Viral Vector Partner for Every Stage of Gene Therapy Development

Gene therapies can correct diseases at their genetic core, but their success hinges on viral vector manufacturing. As gene therapy technology becomes more advanced, producing viral vectors becomes more challenging, requiring a manufacturing partner that is not only versed in viral vector production but also agile enough to adapt to the shifting tides of innovation. A closer look at the experiences of two companies -- NysnoBio, a client of UF Innovate | Accelerate, and bluebird bio -- offers insight into what sponsors at different stages of the development and manufacturing cycle need in a contract development and manufacturing organization (CDMO) partner.

Ascend Acquires Beacon Gene Therapy Manufacturing Site

Ascend Advanced Therapies, a gene therapy development partner, has purchased Beacon Therapeutics’ contract, manufacturing, and controls team—along with the company's site, previously owned by UF Innovate | Accelerate graduate AGTC, located in Alachua, FL—a town considered to be a “biotech hub” in the state. The acquisition introduces a good manufacturing practice (GMP) plant into the fold, along with process and analytical development capabilities.